TIL Expansion Using KCa3.1 Agonists for Better T Cell Phenotypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for expanding tumor infiltrating lymphocytes (TILs) for cancer treatment, such as IL-2-based rapid expansion processes, face challenges in achieving optimal phenotypic characteristics and differentiation, limiting their therapeutic efficacy.
Innovation Solution
Incorporating potassium channel agonists, specifically KCa3.1 agonists, into the cell culture medium during the expansion process of TILs, which enhances TIL proliferation and improves phenotypic characteristics, resulting in a population of TILs with increased CD8+CD28+, CD8+CD27+, CD8+CD27+CD28+, and CCR7+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional IL-2-based TIL expansion methods are used, then TIL numbers can be increased, but the expansion efficiency and phenotypic quality are limited
Solution Approach 1:
The patent introduces potassium channel agonists (specifically KCa3.1 agonists like SKA-31, SKA-20, NS309, and riluzole) as additional culture medium components to modify the expansion parameters. This chemical parameter change enhances both the quantity and phenotypic quality of expanded TILs beyond conventional IL-2 monotherapy, achieving superior expansion efficiency and desirable phenotypic characteristics including increased CD8+CD28+, CD8+CD27+, and CCR7+ T cell populations
2Speed
If rapid expansion process is implemented, then expansion speed increases, but phenotypic characteristics may be compromised
Solution Approach 1:
The patent uses potassium channel agonists as intermediary substances that mediate between the rapid expansion process and phenotypic quality maintenance. These agonists act as signaling modulators that enable fast expansion while preserving and even enhancing desirable phenotypic characteristics, effectively bridging the gap between speed and quality that typically exists in TIL expansion protocols
3Ease of manufacture
If TIL expansion is performed without potassium channel agonists, then the process is simpler, but expansion efficiency and therapeutic efficacy are reduced
Solution Approach 1:
The patent demonstrates that potassium channel agonists serve multiple functions simultaneously: they enhance expansion efficiency, improve phenotypic quality, and maintain process feasibility. The agonists work within existing culture frameworks (comparing well with IL-2 and OKT-3 protocols) while adding therapeutic value, making the enhanced protocol both effective and practically implementable without excessive complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of KCa3.1 agonists during TIL expansion leads to a significant increase in TIL numbers and improves their phenotypic characteristics, enhancing their therapeutic potential for cancer treatment.
Implementation Method 1
The use of potassium channel agonists, specifically KCa3.1 agonists, in the expansion process of TILs
Implementation Method 2
K+ channels fall into four major classes: (1) voltage-gated potassium channels (Kv), which open or in response to variations in transmembrane voltage; (2) calcium-activated potassium channels (KCa), which open in response to the presence of calcium ions or other signaling molecules
Data Source
AI summary
Methods of expanding tumor infiltrating lymphocytes (TILs) using a potassium channel agonist, such as a KCa3.1 (IK channel) agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.